Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC

Epigenetics

Volumn 8, Issue 5, 2013, Pages 486-493

  Ibragimova, Ilsiya ^a   Maradeo, Marie E ^a   Dulaimi, Essel ^a   Cairns, Paul ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

ARID1A; BAP1; Clear cell RCC; KDM5C; KDM6A; MLL2; PBRM1; Promoter methylation; Renal cell carcinoma; SETD2

Indexed keywords

ADULT; AGED; ARTICLE; BAP1 GENE; CHROMATIN MODIFYING GENE; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE; HUMAN; HUMAN CELL; KDM6A GENE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MICROSCOPY; PBRM1 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; SETD2 GENE;

EID: 84877343113     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.24552     Document Type: Article

References (62)

1. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7:277-85; PMID:20448661; http://dx.doi. org/10.1038/nrurol.2010.47.
2. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004; 4:381-93; PMID:15122209; http://dx.doi. org/10.1038/nrc1364.
3. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463:360-3; PMID:20054297; http://dx.doi.org/10.1038/nature08672.
4. Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, et al. Frequent mutations of genes encoding ubiquitinmediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012; 44:17-9; PMID:22138691; http://dx.doi.org/10.1038/ng.1014.
5. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44:751-9; PMID:22683710; http://dx.doi.org/10.1038/ng.2323.
6. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469:539-42; PMID:21248752; http://dx.doi.org/10.1038/nature09639.
7. Duns G, Hofstra RM, Sietzema JG, Hollema H, van Duivenbode I, Kuik A, et al. Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat 2012; 33:1059-62; http://dx.doi.org/10.1002/humu.22090; PMID:22461374.
8. Jones S, Wang TL, Shih IeM, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330:228-31; PMID:20826764; http://dx.doi.org/10.1126/science.1196333.
9. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363:1532-43; http://dx.doi.org/10.1056/NEJMoa1008433; PMID:20942669.
10. Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011; 43:875-8; PMID:21822268; http://dx.doi. org/10.1038/ng.907.
11. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012; 33:100-3; http://dx.doi. org/10.1002/humu.21633; PMID:22009941.
12. van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009; 41:521-3; PMID:19330029; http://dx.doi.org/10.1038/ng.349.
13. Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012; 488:100-5; PMID:22832583; http://dx.doi.org/10.1038/nature11284.
14. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109:3879-84; PMID:22343534; http://dx.doi.org/10.1073/pnas.1121343109.
15. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298-303; PMID:21796119; http://dx.doi.org/10.1038/nature10351.
16. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. Medulloblastoma exome sequencing uncovers subtypespecific somatic mutations. Nature 2012; 488:106-10; PMID:22820256; http://dx.doi.org/10.1038/nature11329.
17. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410-3; PMID:21051595; http://dx.doi. org/10.1126/science.1194472.
18. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43:668-72; PMID:21642991; http://dx.doi. org/10.1038/ng.855.
19. White AE, Harper JW. Cancer. Emerging anatomy of the BAP1 tumor suppressor system. Science 2012; 337:1463-4; PMID:22997315; http://dx.doi. org/10.1126/science.1228463.
20. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358:1148-59; PMID:18337604; http://dx.doi. org/10.1056/NEJMra072067.
21. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; http://dx.doi. org/10.1016/j.cell.2007.01.029.
22. Smits KM, Schouten LJ, van Dijk BA, Hulsbergen-van de Kaa CA, Wouters KA, Oosterwijk E, et al. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008; 14:782-7; PMID:18245539; http://dx.doi.org/10.1158/1078-0432.CCR-07-1753.
23. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, et al. Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004; 10:3972-9; PMID:15217927; http://dx.doi. org/10.1158/1078-0432.CCR-04-0175.
24. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994; 91:9700-4; PMID:7937876; http://dx.doi.org/10.1073/pnas.91.21.9700.
25. Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-30; PMID:7553621.
26. Costa VL, Henrique R, Ribeiro FR, Pinto M, Oliveira J, Lobo F, et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer 2007; 7:133; PMID:17645803; http://dx.doi.org/10.1186/1471-2407-7-133.
27. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, et al. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 2003; 22:6794-801; PMID:14555992; http://dx.doi.org/10.1038/sj.onc.1206914.
28. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res 2009; 69:4674-81; PMID:19470766; http://dx.doi.org/10.1158/0008-5472.CAN-09-0146.
29. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58:3455-60; PMID:9699680.
30. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 1998; 95:6870-5; PMID:9618505; http://dx.doi.org/10.1073/pnas.95.12.6870.
31. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997; 57:808-11; PMID:9041175.
32. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A 1998; 95:8698-702; PMID:9671741; http://dx.doi.org/10.1073/pnas.95.15.8698.
33. Cairns P. Gene methylation and early detection of genitourinary cancer: the road ahead. Nat Rev Cancer 2007; 7:531-43; PMID:17585333; http://dx.doi. org/10.1038/nrc2170.
34. Maradeo ME, Cairns P. Translational application of epigenetic alterations: ovarian cancer as a model. FEBS Lett 2011; 585:2112-20; PMID:21402071; http://dx.doi.org/10.1016/j.febslet.2011.03.016.
35. Issa JP, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res 2009; 15:3938-46; PMID:19509174; http://dx.doi.org/10.1158/1078-0432.CCR-08-2783.
36. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002; 99:3740-5; PMID:11891299; http://dx.doi.org/10.1073/pnas.052410099.
37. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, et al. Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009; 1:177-200; http://dx.doi.org/10.2217/epi.09.14; PMID:22122642.
38. Eckhardt F, Lewin J, Cortese R, Rakyan VK, Attwood J, Burger M, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006; 38:1378-85; PMID:17072317; http://dx.doi. org/10.1038/ng1909.
39. Greenfield A, Carrel L, Pennisi D, Philippe C, Quaderi N, Siggers P, et al. The UTX gene escapes X inactivation in mice and humans. Hum Mol Genet 1998; 7:737-42; PMID:9499428; http://dx.doi.org/10.1093/hmg/7.4.737.
40. Tsuchiya KD, Greally JM, Yi Y, Noel KP, Truong JP, Disteche CM. Comparative sequence and x-inactivation analyses of a domain of escape in human xp11.2 and the conserved segment in mouse. Genome Res 2004; 14:1275-84; PMID:15197169; http://dx.doi. org/10.1101/gr.2575904.
41. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 2002; 167:57-60; PMID:11743275; http://dx.doi.org/10.1016/S0022-5347(05)65382-7.
42. Clark SJ, Statham A, Stirzaker C, Molloy PL, Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006; 1:2353-64; PMID:17406479; http://dx.doi.org/10.1038/nprot.2006.324.
43. Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphitetreated DNA. Nucleic Acids Res 1997; 25:4422-6; PMID:9336479; http://dx.doi.org/10.1093/nar/25.21.4422.
44. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001; 29:E65-5; PMID:11433041; http://dx.doi.org/10.1093/nar/29.13.e65.
45. Sandovici I, Leppert M, Hawk PR, Suarez A, Linares Y, Sapienza C. Familial aggregation of abnormal methylation of parental alleles at the IGF2/H19 and IGF2R differentially methylated regions. Hum Mol Genet 2003; 12:1569-78; PMID:12812984; http://dx.doi. org/10.1093/hmg/ddg167.
46. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-92; http://dx.doi.org/10.1056/NEJMoa1113205; PMID:22397650.
47. Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P. Identification of novel target genes by an epigenetic reactivation screen of renal cancer. Cancer Res 2006; 66:5021-8; PMID:16707423; http://dx.doi.org/10.1158/0008-5472.CAN-05-3365.
48. Ibragimova I, Ibáñez de Cáceres I, Hoffman AM, Potapova A, Dulaimi E, Al-Saleem T, et al. Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) 2010; 3:1084-92; PMID:20699414; http://dx.doi.org/10.1158/1940-6207.CAPR-10-0039.
49. Millar DS, Ow KK, Paul CL, Russell PJ, Molloy PL, Clark SJ. Detailed methylation analysis of the glutathione S-transferase pi (GSTP1) gene in prostate cancer. Oncogene 1999; 18:1313-24; http://dx.doi. org/10.1038/sj.onc.1202415; PMID:10022813.
50. Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, et al. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 1997; 57:2229-37; PMID:9187126.
51. Barrera V, Peinado MA. Evaluation of single CpG sites as proxies of CpG island methylation states at the genome scale. Nucleic Acids Res 2012; 40:11490-8; PMID:23066096; http://dx.doi.org/10.1093/nar/gks928.
52. Li Y, Zhu J, Tian G, Li N, Li Q, Ye M, et al. The DNA methylome of human peripheral blood mononuclear cells. PLoS Biol 2010; 8:e1000533; http://dx.doi. org/10.1371/journal.pbio.1000533; PMID:21085693.
53. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994; 54:6353-8; PMID:7987828.
54. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21:5427-40; http://dx.doi. org/10.1038/sj.onc.1205600; PMID:12154405.
55. Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev 2009; 23:1327-37; PMID:19487573; http://dx.doi. org/10.1101/gad.1777409.
56. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133:647-58; PMID:17681183; http://dx.doi.org/10.1053/j.gastro. 2007.05.022.
57. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97:10014-9; PMID:10954755; http://dx.doi.org/10.1073/pnas.180316197.
58. Sambrook J, Russell DW. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 2001.
59. Foch JaT. G. Chapter 5: New Human Tumor Cell Lines In: Foch J, ed. Human Tumor Cells in Vitro. New York and London: Plenum Press, 1975:115-59.
60. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196:261-82; PMID:3656447; http://dx.doi.org/10.1016/0022-2836(87)90689-9.
61. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63; PMID:7180965; http://dx.doi.org/10.1097/00000478-198210000-00007.
62. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A III. Chapter 43 Kidney. AJCC Cancer Staging Manual Seventh Edition 2009:479-90.